Cybin rebrands as Helus Pharma ahead of Nasdaq listing and ticker change from CYBN to HELP

Cybin is rebranding as Helus Pharma as part of a stock exchange switch, with the goal of repositioning the company and its investor messaging. Cybin plans to stop trading on the NYSE American on January 4, 2026, and begin trading on the Nasdaq Global Market on January 5, 2026. Alongside the relisting, the company will change its stock ticker from CYBN to HELP, and will also update its Cboe Canada ticker to HELP on January 5. The rebrand keeps Cybin Helus tied to psychedelic R and D, with an R and D pipeline focused on psilocybin-related molecules and DMT. As Helus, the company is aiming to deliver clinical data in major depressive disorder (MDD) and generalized anxiety disorder (GAD), including top-line data for a deuterated DMT prospect in GAD in Q1 2026 and top-line phase 3 data on a deuterated psilocybin analog in MDD in Q4 2026.